This paper is in the following e-collection/theme issue:

Qualitative Methods (71) HIV/AIDS/STI Prevention and Care (879) Protocols for Public Health Research and Surveillance (69)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/47700, first published .
Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study

Authors of this article:

Joyeeta Mukherjee1 Author Orcid Image ;   Shruta Rawat2 Author Orcid Image ;   Saif ul Hadi1 Author Orcid Image ;   Pritha Aggarwal1 Author Orcid Image ;   Venkatesan Chakrapani3 Author Orcid Image ;   Pratyasha Rath4 Author Orcid Image ;   Pallavi Manchi4 Author Orcid Image ;   Srikrishnan Aylur5 Author Orcid Image ;   Shelly Malhotra6 Author Orcid Image ;   Margaret Keane6 Author Orcid Image ;   Alok Gangaramany4 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics

Journals

  1. Malhotra S, Cameron A, Gotham D, Burrone E, Gardner P, Loynachan C, Morin S, Scott C, Pérez-Casas C, Pai M. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries. PLOS Global Public Health 2024;4(7):e0003418 View